Evaluation of Intrathecal Hyperbaric Bupivacaine With Dexmedetomidine in Adults Undergoing Perianal Surgery
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Duration of analgesia
Study Overview
Brief Summary
The aim of this study is to evaluate the effects of adding 5-mcg dexmedetomidine to hyperbaric bupivacaine in our population as it has never been published before, to enhance the duration of analgesia after perianal procedures requiring spinal saddle block and, thus reducing requirements of postoperative analgesics.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 40 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients undergoing elective perianal surgery under spinal saddle block were included in the study.
- •Age between 40-80 years
- •ASA status I and II
Exclusion Criteria
- •Pregnant women
- •Patient with coagulopathy
- •Infection at or near the needle insertion site
- •Allergy to the trial drug
- •Patient with chronic pain
- •Cognitive impairment
- •Patient with known drug or substance abuse
Arms & Interventions
Dexemedetomidine
Experimental group received intrathecal dexmedetomidine 5 microgram added to 5 mg of 0.5% hyperbaric bupivacaine in dextrose injection
Intervention: Dexmedetomidine (Drug)
Hyperbaric bupivacaine
Active comparator had 5 mg of 0.5% hyperbaric bupivacaine in dextrose injection alone
Intervention: Hyperbaric bupivacaine % 0.5 (Drug)
Outcomes
Primary Outcomes
Duration of analgesia
Time Frame: 0 hour to 4 hours
duration of analgesia was assessed from induction of anesthesia till patient discharge
Secondary Outcomes
- Pain score(Two hours post surgery till 24 hours)
Investigators
Fahad Ali Tunio
Principal Investigator
Liaquat National Hospital & Medical College